Cordella PA Sensor Coin

Endotronix Announces Positive Data from the SIRONA First-in-Human Trial for the Cordella™ PA Pressure Sensor System

LISLE, IL – November 18, 2019 – Seroba’s portfolio company, Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella™ Pulmonary Artery (PA) Pressure Sensor System (Cordella Sensor).  Data was presented at the 2019 American Heart Association (AHA) Scientific Sessions in Philadelphia, PA by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

“Chronic heart failure patients too frequently have cycles of decompensation and hospitalization that negatively impact patient outcomes and drive up treatment costs. Recent data shows that using PA pressure-guided therapy with this population keeps them healthier and out of the hospital,” stated Prof. Dr. Mullens. “The Cordella System is an elegant solution that integrates a PA pressure sensor and a comprehensive patient management platform in one. The straightforward sensor implant provides reliable pressure data, while the patient management platform enables a comprehensive clinical picture of the patient that allows my team to make informed therapy decisions and improve outcomes.”

The 90-day results from the first-in-human trial confirm the device safety and accuracy of pressure measurements in the right pulmonary artery using the implanted Cordella Sensor and handheld patient reader. The study included 15 patients across two European sites: Prof. Dr. Mullens in Belgium and Dr. Faisal Sharif of the National University of Ireland (NUI) in Galway, Ireland.

Highlights include:
• The primary accuracy endpoint was met with no significant difference in measured mean PA pressure for the Cordella Sensor and the reference catheter at 90 days.
• The study demonstrated encouraging safety results with zero Device Related System Complications (DSRC) at 90 days.
• High patient compliance (>98%) with daily remote measurements of vital signs and PA pressure throughout the study.

“The presentation of our first-in-human data at AHA this year is another exciting milestone for the company,” commented Dr. Katrin Leadley, Chief Medical Officer of Endotronix. “This work lays the clinical foundation for our groundbreaking IDE trial, PROACTIVE-HF, which will begin enrollment in the U.S. later this year. Designed to provide the highest level of clinical evidence for PA pressure-guided therapy, PROACTIVE-HF will support U.S. market access of the Cordella Sensor and inform a national coverage decision from the Centers for Medicare & Medicaid Services (CMS).”

The Cordella Sensor is not available for commercial use in any geography and is under clinical investigation in Europe (SIRONA II CE Mark Trial) and the U.S. (PROACTIVE-HF IDE Trial). CAUTION – Investigational Device. Limited by Federal (or United States) Law to Investigational Use. Exclusively for clinical investigations. The Cordella System, without the sensor, is available for commercial use in the U.S. and E.U. and is currently in cardiology centers across the U.S.

About the Cordella™ Heart Failure System
The Cordella Heart Failure System (Cordella System) is designed to help patients suffering from chronic heart failure feel better and stay out of the hospital with streamlined care and remote medication titration. The system provides a comprehensive health status of the patient at home with easy-to-use tools to securely collect and share health related data with healthcare providers for trend-based management. The Cordella Sensor seamlessly integrates pulmonary artery (PA) pressure data into the Cordella System. Together, they proactively deliver the information necessary to improve patient care between office visits and support reimbursement for care delivery activities.

About Endotronix
Endotronix, Inc., is a medical technology company focused on advancing the treatment of chronic heart failure. Privately held, the company is backed by world-class medtech investors including Aperture Venture Partners, BioVentures Investors, LSP, Lumira Ventures, OSF Ventures, Seroba Life Sciences, Skydeck LLC, SV Health Investors, Wanxiang Healthcare Investments, and two unnamed corporate strategic investors.  Learn more at www.endotronix.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release may contain predictions, estimates or other information that might be considered forward-looking statements.  Such forward-looking statements are not a guarantee of future performance.

Recent Articles

Treating Heart Failure

Endotronix Announces Partnership with Tyndall National Institute.

DUBLIN, IRELAND – October 15, 2019 – Seroba’s portfolio company, Endotronix Ireland Limited, a digital health and medical technology company […]

Read More
Pq Bypass News 2

PQ Bypass Announces Unconditional IDE Approval from U.S. FDA for Pivotal Study.

MILPITAS, Calif. & Dublin, Ireland.  October 8, 2019. PQ Bypass Announces Unconditional IDE Approval from U.S. FDA to Start TORUS […]

Read More
Treating Heart Failure

Endotronix Closes Expanded Series D Round

Lisle, IL & Dublin Ireland – Oct 1, 2019   Seroba’s investee company, Endotronix, Inc., a digital health, medtech company dedicated […]

Read More
Storm RNA Epigenetics Conference

STORM Therapeutics Presents Breakthrough Data at RNA Epigenetics Conference.

STORM Therapeutics presents breakthrough data showing in vivo efficacy and therapeutic proof of concept for targeting RNA modifying enzymes. 18 […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top